<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04178135</url>
  </required_header>
  <id_info>
    <org_study_id>P2019005</org_study_id>
    <nct_id>NCT04178135</nct_id>
  </id_info>
  <brief_title>Recombinant LH Supplementation Timing Strategies (From Day 1 or Day 6) to a Standard GnRH Agonist Long Protocol in Subsequent COS Cycle of Older Patients With Unexpected Poor or Suboptimal Ovarian Response</brief_title>
  <official_title>Recombinant LH Supplementation Timing Strategies (From Day 1 or Day 6) to a Standard GnRH Agonist Long Protocol in Subsequent COS Cycle of Older Patients With Unexpected Poor or Suboptimal Ovarian Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reproductive &amp; Genetic Hospital of CITIC-Xiangya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reproductive &amp; Genetic Hospital of CITIC-Xiangya</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, controlled, pilot study, for Patients ≥ 35 years and &lt; 40 years old with
      sufficient ovarian reserve parameters (AFC≥ 5), but showed an unexpected poor or suboptimal
      ovarian response(defined as ≤ 9 retrieved oocytes in previous full-stimulation cycle, but not
      get live birth after all embryos were used ). In order to get better oocyte number and
      quality in the new COS cycle, we will compare LH supplementation from beginning with from
      middle of stimulation in GnRH-a long protocol.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 25, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of gestational sacs</measure>
    <time_frame>Day 28 after embryo transfer</time_frame>
    <description>Number of gestation sac will be detected by ultrasonographic visualization</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infertility,Female</condition>
  <arm_group>
    <arm_group_label>rLH supplementation from day 1 of stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rLH supplementation from day 1 of stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rLH supplementation from day 6 of stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rLH supplementation from day 6 of stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rLH</intervention_name>
    <description>rLH supplement from day 1 of stimulation</description>
    <arm_group_label>rLH supplementation from day 1 of stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rLH</intervention_name>
    <description>rLH supplement from day 6 of stimulation</description>
    <arm_group_label>rLH supplementation from day 6 of stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Infertile women, 35≤ Age&lt; 40 years 2.18&lt;BMI&lt;28 Kg/m2 3.5 ≤AFC ≤20 4.Basal serum FSH≤10
        IU/L, E2&lt;70 pg/ml 5.Previous cycle as the first COS cycle,AFC ≥ 5,starting dose of FSH
        between 150 IU and 300IU with the possibility of adding r-hLH or hMG later in the cycle,
        number of oocytes retrieved ≤9 (4-9 oocytes retrieval as suboptimal responder and &lt;4
        oocytes retrieval as unexpected poor responder), but not get live birth after all embryos
        were used.

        6.Normal uterus and at least one side of the normal ovary 7.GnRH-a long protocol, using
        Gonal-F® 300IU and Luveris® 150IU for COS 8.Informed consent form signed 9.Willing to
        follow the study protocol, and able to complete this study

        Exclusion Criteria:

          1. Moderate and Severe endometriosis

          2. PCOS

          3. Previous ovarian surgery history

          4. History of recurrent miscarriages (&gt;2 times of miscarriages)

          5. Any major systemic disease that as per Investigator's discretion precludes subject for
             participation in the study

          6. With pregnancy contraindications Alcoholism, drug abuse, drug addiction or patients
             with uncured sexually transmitted disease

          7. According to the judgment of the Investigator, any medical condition or any
             concomitant surgery/medications that would interfere with evaluation of study
             medications

          8. Simultaneous participation in another clinical study

          9. Plan to use other Gn other than Gonal-F® or Luveris® during COS treatment Thyroid
             gland disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Months</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sufen Cai, Doctor</last_name>
    <phone>0731-82355100</phone>
    <email>ajiu0305@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Reproductive &amp; Genetic Hospital of CITIC-XIANGYA</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sufen Cai, doctor</last_name>
      <phone>0731-82355100</phone>
      <email>ajiu0305@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 24, 2019</study_first_submitted>
  <study_first_submitted_qc>November 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>poor or suboptimal ovarian response,GnRH agonist long protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

